European Cancer Guidelines Add Delcath Liver Therapy for Eye Melanoma

European Cancer Guidelines Add Delcath Liver Therapy for Eye Melanoma

The ESMO-EURACAN clinical practice guidelines now include Delcath's CHEMOSAT hepatic delivery system as a recommended liver-directed therapy for metastatic uveal melanoma. The decision, supported by two Phase 3 trials, strengthens the therapy's regulatory and commercial positioning in Europe, giving business development teams and investors a clear catalyst to track.

IntelligenceRegulatory Impact▾

the FDA and EMA are the bodies to watch. Regulatory relevance reads high for oncology, with CHEMOSAT most exposed to upcoming decisions. Teams should track submission types, designations, and any guidance shifts that could move approval timelines.

Key Takeaways

• ESMO-EURACAN guidelines now recommend Delcath's CHEMOSAT for metastatic uveal melanoma, citing two Phase 3 trials.
• The recommendation lists CHEMOSAT first among regional liver-directed therapy options, a positioning already reflected in NCCN guidance.
• Investors should watch reimbursement negotiations and market access developments in Europe as the next major catalyst.

IntelligenceCompetitive Intelligence▾

Competitive pressure is medium. Delcath Systems, Inc. stand to gain or defend position here. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

The Development

On April 6, 2026, Delcath Systems announced that the ESMO–EURACAN clinical practice guidelines for uveal melanoma have added CHEMOSAT (melphalan hepatic delivery system) as a recommended liver-directed regional therapy. The guideline specifically cites two Phase 3 trials and lists the therapy first among regional options, extending recognition already reflected in NCCN guidance.

Uveal melanoma, the most common primary intraocular cancer in adults, has a distinct metastatic pattern: roughly half of patients develop liver-dominant disease. The National Cancer Institute notes that surgery — including resection and enucleation — remains the most common treatment for the primary tumor, but once the disease spreads to the liver, systemic options are limited. Liver-directed therapies like CHEMOSAT fill a critical gap.

Delcath's system delivers a high dose of melphalan directly to the liver while filtering the drug from the venous return before it reaches the systemic circulation. Clinical evidence shows that repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. The technical approach continues to evolve: a 2021 study provided the first description of radial artery access for hepatic chemosaturation, demonstrating technical feasibility for a less invasive delivery route.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high. Expect implications for oncology pricing, access, and launch sequencing.

What This Means for Pharma Teams

For business development teams, guideline inclusion signals a validated clinical pathway that may accelerate partnership discussions and licensing deals in Europe. The ESMO-EURACAN imprimatur carries weight with hospital formulary committees, purchasing groups, and national health technology assessment bodies. Delcath now has a clear playbook: secure reimbursement in key European markets, then target centers of excellence for uveal melanoma.

Investors should view this as a catalyst for reimbursement negotiations and potential revenue growth. The guideline positions CHEMOSAT alongside tebentafusp, which the ESMO–EURACAN panel designates as standard of care for HLA-A*02:01-positive patients in the first-line metastatic setting — unless liver-directed treatment modalities are appropriate. That carve-out matters: it gives CHEMOSAT a defined niche rather than forcing a head-to-head competition with immunotherapy.

Analysts should compare CHEMOSAT's positioning against other liver-directed therapies and monitor for competitive filings. The guideline's multidisciplinary emphasis means Delcath needs to build relationships with medical oncologists, interventional radiologists, and surgical oncologists who treat uveal melanoma patients. Reimbursement conversations with national health authorities in Germany, France, and Italy will be the next real test of commercial viability.

Frequently Asked Questions

IntelligenceStrategic Takeaways▾

ESMO-EURACAN guidelines now recommend Delcath's CHEMOSAT for metastatic uveal melanoma, citing two Phase 3 trials. The recommendation lists CHEMOSAT first among regional liver-directed therapy options, a positioning already reflected in NCCN guidance. Investors should watch reimbursement negotiations and market access developments in Europe as the next major catalyst.

What to Watch Next

The guideline inclusion removes a key barrier to adoption, but it does not write prescriptions. Delcath's next milestones will be reimbursement decisions in major European markets, particularly Germany (via AMNOG), France (via HAS), and the UK (via NICE). Each country has its own health technology assessment process, and guideline recommendations carry different weight in each system.

Investors should also watch for expansion of the clinical evidence base. The efficacy and safety data for the melphalan/hepatic delivery system continue to accumulate, and Delcath may pursue label expansions or combination studies that could broaden the addressable patient population. For now, the European guidelines give the company a credible platform to build commercial momentum — and a clear story to tell partners, payers, and prescribers.

Related coverage

• 데일리팜 리크루트: Vyloy (zolbetuximab) Reimbursement Progress and Market Implications for Gastric Cancer
• Circulating Biomarkers: Additional Evidence Supporting Their Clinical Use in Breast Cancer
• Cynata Therapeutics (ASX:CYP) Surges on European Regulatory Milestone for CYP-001